|
Development of anti-obesity drug (Hiroshima University, Assoc.Prof. Toru Hosoi)
new therapeutic strategy for improving leptin resistance
The development of this therapeutic agent is developed based on the concept
that obesity is not just due to caloric imbalance, but rather results from a condition called “leptin resistance” that causes physiological symptoms. Since this therapy uses a non-steroidal anti-inflammatory agent that has already been approved for other indications, the clinical development time is expected to be considerably shorter than with other new drugs. To access the rest of the information on this page,
|
|
TECHNOLOGY
SEARCH 
|
|